US OptionsDetailed Quotes
MNMD240719C9000
- 0.04
- 0.000.00%
15min DelayClose Jul 19 13:52 ET
0.00High0.00Low
0.00Open0.04Pre Close0 Volume0 Open Interest9.00Strike Price0.00Turnover1002.48%IV3.67%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.1099Delta0.2390Gamma218.00Leverage Ratio-2.0327Theta0.0000Rho23.95Eff Leverage0.0001Vega
Mind Medicine Stock Discussion
$Mind Medicine(MNMD.US)$
$36 target!!!!!
https://www.moomoo.com/news/post/41181597/roth-mkm-initiates-mind-medicine-mnmdus-with-buy-rating-announces?futusource=news_stock_stockpagenews&ns_stock_id=37125992&report_id=37125992&report_type=stock&src=2&main_broker=WzEwMDdd&client_hour_clock=24&us_cid=73925127&channel=4&skintype=3&level=2&global_content={%22promote_content%22:%22mm:post:41181597%22,%22invite%22:73925127}&data_ticket=1721821266767476
$36 target!?!?
https://www.moomoo.com/news/post/41181597?futusource=news_stock_stockpagenews&ns_stock_id=37125992&report_id=37125992&report_type=stock&src=2&main_broker=WzEwMDdd&client_hour_clock=24&us_cid=73925127&channel=4&skintype=3&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Apost%3A41181597%22%2C%22invite%22%3A73925127%7D&data_ticket=d852726825d53ffa91432d8eef415178
A small position however, it isn't showing up on the ticker at all!
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
MindMed Announces Issuance of New Patent for Mm120 Orally Disintegrating Tablet (Odt)
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
MindMed (NASDAQ: MNMD) has been granted a new patent by the USPTO for its MM120 (lysergide) orally disintegrating tablet (ODT) formulation. This patent, extending protection until 2041, covers the pharmaceutical formulation, manufacturing methods, and treatment applications for MM120 ODT. The formulation incorporates Catalent's Zydis® ODT technology, which MindMed believes will offe...
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
No comment yet